Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × elacestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Cyclophosphamide 787 Carboplatin 683 Paclitaxel 638 Bevacizumab 631 pembrolizumab 602 Cisplatin 599 Gemcitabine 535 Docetaxel 501 Rituximab 486 Radiotherapy 481 Dexamethasone 431 Nivolumab 410 Doxorubicin 385 Capecitabine 339 Fluorouracil 338 Etoposide 313 Oxaliplatin 291 Cytarabine 287 Pemetrexed 287 Lenalidomide 284 Prednisone 282 Erlotinib Hydrochloride 274 fludarabine phosphate 271 Leucovorin 263 fludarabine 261 Trastuzumab 254 Filgrastim 247 Bortezomib 246 Vincristine 246 Cetuximab 233

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡